Physician profile
Frank Wang
NPI 1821286451
$10,915.50
in general payments reported to CMS, 2019-2025
53 companies · $1,188 in 2025
The $1,188 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,831 · 2020: $1,810 · 2021: $2,051 · 2022: $1,438 · 2023: $1,379 · 2024: $1,219 · 2025: $1,188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,786.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,785.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,660.61 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $893.78 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Lilly USA, LLC | $880.27 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $825.07 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $645.56 | 2019-2024 | Xifaxan, Trulance |
| Astrazeneca Pharmaceuticals Lp | $526.34 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Janssen Pharmaceuticals, INC | $429.63 | 2019-2023 | Xarelto |
| Amarin Pharma, INC. | $428.97 | 2019-2022 | |
| Allergan, INC. | $419.45 | 2019-2020 | |
| Glaxosmithkline, LLC. | $409.51 | 2019-2025 | Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $390.38 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $330.08 | 2021-2025 | |
| Amgen INC. | $289.83 | 2019-2025 | Evenity, Prolia, Repatha |
| Exact Sciences Corporation | $286.30 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $264.10 | 2019-2020 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.